



General Assembly

February Session, 2026

**Raised Bill No. 5482**

LCO No. 1203



Referred to Committee on HUMAN SERVICES

Introduced by:  
(HS)

***AN ACT CONCERNING TWELVE-MONTH COVERAGE FOR  
CONTRACEPTION AND HORMONE THERAPY.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective January 1, 2027*) (a) As used in this section,  
2 "prescription hormone therapy" means all drugs approved by the  
3 United States Food and Drug Administration that are used to medically  
4 suppress, increase or replace hormones that the body is not producing  
5 at intended levels, as determined by the prescribing provider.  
6 "Prescription hormone therapy" does not include glucagon-like peptide-  
7 1 and glucagon-like peptide-1 receptor agonists.

8 (b) Each individual and group health insurance policy providing  
9 coverage of the type specified in subdivisions (1), (2), (4), (11) and (12)  
10 of section 38a-469 of the general statutes, delivered, issued for delivery,  
11 renewed, amended or continued in this state on or after January 1, 2027,  
12 that includes coverage for prescription hormone therapy shall provide  
13 reimbursement for a twelve-month supply of covered prescription  
14 hormone therapy and any necessary supplies for administration  
15 dispensed at one time, unless the (1) insured requests a smaller supply,

16 (2) prescribing provider instructs that the insured must receive a smaller  
17 supply, or (3) prescription hormone therapy is a controlled substance. If  
18 the prescription hormone therapy is a controlled substance, the health  
19 plan shall provide reimbursement for the maximum refills allowed  
20 under state and federal law to be obtained at one time by the insured.

21 (c) Nothing in this section prohibits a health plan from limiting refills  
22 that may be obtained in the last quarter of the plan year if a twelve-  
23 month supply of the prescription hormone therapy has already been  
24 dispensed during the plan year. To the extent not otherwise prohibited  
25 under state or federal law, health plans may apply drug utilization  
26 management strategies to prescription drugs covered under this section.

27 Sec. 2. (NEW) (*Effective January 1, 2027*) (a) As used in this section, (1)  
28 "medically necessary" has the same meaning as provided in section 17b-  
29 259b of the general statutes; and (2) "prescription hormone therapy"  
30 means all drugs approved by the United States Food and Drug  
31 Administration that are used to medically suppress, increase or replace  
32 hormones that the body is not producing at intended levels, as  
33 determined by the prescribing provider. "Prescription hormone  
34 therapy" does not include glucagon-like peptide-1 and glucagon-like  
35 peptide-1 receptor agonists.

36 (b) The Commissioner of Social Services, to the extent permissible  
37 under federal law, shall provide Medicaid coverage for a medically  
38 necessary twelve-month supply of prescription hormone therapy and  
39 any necessary supplies for administration dispensed at one time, unless  
40 the (1) enrollee requests a smaller supply, (2) prescribing provider  
41 instructs that the enrollee must receive a smaller supply, or (3)  
42 prescription hormone therapy is a controlled substance. If the  
43 prescription hormone therapy is a controlled substance, the  
44 commissioner shall provide Medicaid coverage for the maximum refills  
45 allowed under state and federal law to be obtained at one time by the  
46 Medicaid enrollee.

47 Sec. 3. (NEW) (*Effective January 1, 2027*) The Commissioner of Social

48 Services, to the extent permissible under federal law, shall provide  
49 Medicaid coverage for a twelve-month supply of any prescribed  
50 contraceptive drug, device or product approved by the United States  
51 Food and Drug Administration and dispensed at one time, unless the  
52 Medicaid enrollee or the enrollee's prescribing health care provider  
53 requests less than a twelve-month supply of such contraceptive drug,  
54 device or product.

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>January 1, 2027</i>	New section
Sec. 2	<i>January 1, 2027</i>	New section
Sec. 3	<i>January 1, 2027</i>	New section

**HS**      *Joint Favorable*